TABLE 2

Parasitemia and maximum peaks of parasitemia in T. cruzi-infected mice treated with lychnopholide i.v. using different treatment schemes during acute infectiona

Treatment (dose [mg/kg])dStrain and treatment schemeb
CL strain, expt ICL strain, expt IIY strain, expt IIIY strain, expt IV
Subpatent PAR/totalcMPP ± SE (104) (% reduction)eSubpatent PAR/totalMPP ± SE (104) (% reduction)Subpatent PAR/totalMPP ± SE (104) (% reduction)Subpatent PAR/totalMPP ± SE (104) (% reduction)
Untreated0/8223.4 ± 40.8 (ND)0/8244.7 ± 24.3 (ND)0/8163.9 ± 12.9 (ND)0/8123.8 ± 7.8 (ND)
Benznidazole (50)8/82.8 ± 0.9 (98.6)A8/81.2 ± 0.6 (99.2)A0/85.3 ± 1.3 (94.35)A7/82.2 ± 0.5 (97.9)A,D
Free LYC (2)1/888.6 ± 26.8 (56.3)A,B,C1/886.5 ± 27.4 (57.7)A,B,C,D0/890.6 ± 19.4 (37.85)A,B,C0/8ND
LYC-PCL NC (2)5/87.1 ± 2.7 (96.3)A,C8/83.3 ± 1.3 (98.3)A,C,D4/84.0 ± 1.7 (96.9)A6/85.3 ± 1.4 (94.9)A,D
LYC-PLA-PEG NC (2)NDND8/81.5 ± 0.2 (99.3)ANDND8/80.6 ± 0.1 (99.7)A
  • a Female Swiss albino mice (20 to 25 g) were infected with 104 blood trypomastigotes/ml.

  • b Treatment schemes are shown in more detail in Table 1.

  • c Subpatent PAR/total, number of mice with a negative fresh blood examination during the acute phase of the infection divided by the total number of infected animals; MPP, maximum peak of parasitemia; ND, not determined.

  • d Untreated, in this table the untreated group represents all the control groups, including untreated, unloaded PCL NC, unloaded PLA-PEG, and control solution.

  • e The percent parasitemia reduction was based on untreated controls because there were no significant differences between the control groups (untreated, unloaded NC, and control solution). P values of <0.05 indicated significant differences and are denoted by superscript capital letters as follows: A, different from controls; B, different from LYC-PCL NC; C, different from BZ; and D, different from LYC-PLA-PEG).